within Pharmacolibrary.Drugs.ATC.L;

model L01BA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0013,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00017999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00044,
    k12             = 10,
    k21             = 10
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Methotrexate is an antimetabolite and antifolate drug used in the treatment of various cancers, including leukemia, lymphoma, and solid tumors, as well as autoimmune diseases like rheumatoid arthritis and psoriasis. It acts by inhibiting dihydrofolate reductase, preventing DNA synthesis, and cell replication. Methotrexate is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients after intravenous administration.</p><h4>References</h4><ol><li><p>Nader, A, et al., &amp; Wilby, KJ (2017). Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters. <i>European journal of drug metabolism and pharmacokinetics</i> 42(2) 221–228. DOI:<a href=&quot;https://doi.org/10.1007/s13318-016-0338-1&quot;>10.1007/s13318-016-0338-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27059845/&quot;>https://pubmed.ncbi.nlm.nih.gov/27059845</a></p></li><li><p>Bischoff, KB, et al., &amp; Longstreth, JA (1971). Methotrexate pharmacokinetics. <i>Journal of pharmaceutical sciences</i> 60(8) 1128–1133. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600600803&quot;>10.1002/jps.2600600803</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5127083/&quot;>https://pubmed.ncbi.nlm.nih.gov/5127083</a></p></li><li><p>Nelson, RW, &amp; Frank, JT (1981). Intrathecal methotrexate-induced neurotoxicities. <i>American journal of hospital pharmacy</i> 38(1) 65–68. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7011005/&quot;>https://pubmed.ncbi.nlm.nih.gov/7011005</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BA01;
